SISTER

/

SISTER is a phase-2, prospective, randomized, placebo-controlled, blinded, dose-finding trial that aims to determine the safety and preliminary efficacy of TS23. TS23 is a monoclonal antibody against the alpha-2 antiplasmin (α2-AP), in acute ischemic stroke.

The study will be conducted at up to 50 U.S. sites and enroll 300 adults (>18 years) with acute ischemic stroke who have a baseline NIHSS >6 and are able to receive study drug within 4.5-24 hours after stroke onset (or last known well) who have evidence of core-penumbra mismatch on baseline perfusion imaging and are not planned for endovascular intervention or standard of care intravenous (IV) thrombolysis.

TESTED

/

The overall goal of the TESTED study, we will compare the risks and benefits of EVT to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.

DOCUMENTS:

Inclusion Exclusion Criteria

INFORMED CONSENT:

Informed Consent - Participant

Informed Consent - Caregiver

MISC:

Website

DISCOVERY

/

The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients.

Sleep SMART

/

The primary goals of this study are to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality during 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.

CREST-2

/

CREST-2 is designed to compare three different methods of stroke prevention to find the safest and most effective treatment: intensive medical management alone compared to intensive medical management in combination with carotid enarterectomy and carotid stenting.

ASPIRE

/

To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke or death from any cause in patients with recent ICH and atrial fibrillation. Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

ARCADIA

/

To determine if apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy, and to determine if the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

FASTEST

/

The objective of the FASTEST Trial is to establish the first treatment for acute spontaneous ICH within a time window and subgroup of patients that is most likely to benefit. Hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of participants most likely to benefit, will improve outcomes at 180 days as measured by the mRS and decrease ongoing bleeding as compared to standard therapy.

ENDOLOW

/
 
 

This study will test the hypothesis that patients presenting within 8 hours of onset with cerebral ischemia in the setting of proximal LVO and low baseline NIHSS scores (0-5) will have better 90-day clinical outcomes (mRS distribution) with immediate mechanical thrombectomy (iMT) compared to initial medical management (iMM).

DOCUMENTS:

Inclusion Exclusion criteria

Flowsheet

INFORMED CONSENT:

Informed Consent

MISC:

ENDOLOW Website

 

MOST

/

The goal of this study is to determine the effectiveness of combining tPA with blood thinners argatroban or eptifibatide. The research will look at whether combining tPA with either argatroban or eptifibatide will produce better results in stroke patients in the first 90 days after suffering a stroke versus tPA with a placebo.